乳腺癌患者基因检测受质疑
2019-09-16 抗癌健康网
专注健康 关爱生命美国科学家们对接受基因检测的患者进行跟踪调查，结果发现，有1/3的乳腺癌早期患者在接受基因组检测后，没有感觉到这些检测结果对治疗行为具有指导意义，因不能理解基因组检测的数据意义无法与主治医生讨论相关治疗问题，她们普遍关注的问题是，通过基因检测后是否能预测复发的记录。有1/4的患者表示，接受基因检测结果后，感到沮丧。这篇关于癌症早期基因组检测的争议性文章发表在Cancer在线版上。
来自Lineberger Comprehensive Cancer Center的科学家对乳腺癌患者基因检测提出质疑。基因组检测在早期乳腺癌患者中变得越来越常见，基因检测过程主要探测21个与乳腺癌相关的基因，在接受外科手术后，这些基因的表达量可以预示乳腺癌的复发几率。这些检测结果可以帮助患者与医生，指导治疗策略，比如，是否通过化疗来解决复发问题。
如果被检测者显示出具有较高的复发率，那么医生将给患者更为激烈的治疗方案；如果被检测者显示出较低的复发率，那么医生将采取相对保守的治疗方案。
在为期5年的跟踪调查中，科学家们对接受乳腺癌风险基因检测的患者进行问卷调查，结果发现，大部分的患者表示愿意接受这种检测，并且相信这个检测对乳腺癌的治疗和预防复发具有积极的意义，但是，仍旧有部分（1/3）患者表示，虽然进行了检查，但是却不能了解检测结果的真正含义，有1/4的患者表示，对检测结果表示出更大的焦虑。
这些结果表明，基因检测变得越来越常规，患者也十分接受这种检测，但是，美中不足的是，医生与患者间的沟通解释比较缺乏，还有更一步上升的空间。(生物谷Bioon.com)
生物谷推荐原文出处：
Cancer doi:10.1002/cncr.24990
Women's experiences with genomic testing for breast cancer recurrence risk
Janice P. Tzeng, MPH 1, Deborah Mayer, PhD, RN 2, Alice R. Richman, PhD 1, Isaac Lipkus, PhD 3, Paul K. Han, MD, MA, MPH 4, Carmina G. Valle, MPH 5, Lisa A. Carey, MD 6, Noel T. Brewer, PhD 1 *
1Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, North Carolina
2School of Nursing, University of North Carolina, Chapel Hill, North Carolina
3School of Nursing, Duke University, Durham, North Carolina
4Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
5Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina
6Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
ABSTRACT
BACKGROUND:
Few studies have examined how patients understand and use genomic test results when deciding about treatment. This study examined how women receive and incorporate results of Oncotype DX, a genomic test that offers recurrence risk estimates, into decisions about adjuvant treatment for early stage breast cancer.
METHODS:
Participants in the cross-sectional study were 77 women with early stage, estrogen receptor-positive breast cancer with 0 to 3 positive lymph nodes who received Oncotype DX between 2004 and 2009. Mailed surveys, supplemented by medical chart review, assessed how women received and understood recurrence risk information based on the test.
